Antibody-based drug helps ‘bridge’ leukemia patients to curative treatment

Posted by on June 12, 2016 2:58 pm
Categories: health

In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.

Leave a Reply

Your email address will not be published. Required fields are marked *